EDMUND KENNETH KERUT, MD

 

CLINICAL STUDIES:

1. Harch PG, Kerut EK, Van Meter K. Demonstration and Explanation of the Breach of the Pulmonary Filter with Transesophageal Bubble Contrast Echocardiography. Undersea Biomedical Research, 1992, (19:suppl.), 41.


2. Co-Investigator, LIFE Trial (Losartan Intervention For Endpoint reduction in hypertension) LSU Medical Center, Cardiovascular Research Laboratory New Orleans, Louisiana (1995 )


3. Co-Investigator, SISH (Stage I Systolic Hypertension) LSU Medical Center School of Medicine New Orleans, Louisiana (1995 )


4. Co-Investigator, ANA-756 (A Randomized, Double-Blind, Placebo- Controlled Comparison of ANA-756 and Losartan in (Essential Hypertension) LSU Medical Center, Cardiovascular Research Laboratory New Orleans, Louisiana (1996 )


5. Co-Investigator MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure LSU Medical Center, Cardiovascular Research Laboratory New Orleans, Louisiana (1996)


6. Co-Investigator BC14809B (The Effect of Ro 40-5967 on ETT duration (6 months) and on all causes of Mortality in Comparison with Placebo in Patients with Chronic Heart Failure (NYHA Class II-IV) treated for approximately 3 years LSU Medical, Center Cardiovascular Research Laboratory New Orleans, Louisiana (1994 )


7. Co-Investigator, ATLAS (Assessment of Treatment with Lisinopril And Survival) LSU Medical Center Cardiovascular Research Laboratory New Orleans, Louisiana (1992 )


8. Co-Investigator, ACT (Study of the Safety and the Pharmacodynamic Effects of SR33589B Administered Orally for One Month to Patients with Left    Ventricular Dysfunction) LSU Medical Center, Cardiovascular Research Laboratory New Orleans, Louisiana (1996)


9. Principal Investigator, 1518US/0006 (A Trial to Investigate the Effect of Lisinopril and Nisoldipine Combination Therapy on Heart Rate Variability in Diabetic     Patients with Left Ventricular Dysfunction) LSU Medical Center, Cardiovascular Research Laboratory New Orleans, Louisiana (1996 - 1998)


10. Sub-Investigator, PURSUIT, Receptor Suppression Using Integrelin Therapy (Platelet IIb/IIIa in Unstable Angina) (1996 - 1997)


11. Principal Investigator, CV137-013 (Pilot Evaluation of the Effects of the DMP Inhibitor BMS-186716 on Functional Capacity in Subjects with Heart Failure) (1996 - 1998)


12. Principal Investigator, CV137-018 (Evaluation of the Safety/Tolerability of Long-Term Treatment with the DMP Inhibitor BMS-186716 or Lisinopril in Subjects with Heart Failure) (1996 )


13. Principal Investigator, Parke-Davis #981-176/Pfizer #258/101 (A 54-Week Open Label Assessment of the Safety and Efficacy Profile of Atorvastatin as Compared to Fluvastatin, Lovastatin, Simvastatin, and Pravastatin When Used to Optimally Control Primary Hyper-cholesterolemia (Type IIA) and Mixed Dyslipidemia  (Type IIB)  (1997 -1999)


14. Principal Investigator, Bristol-Meyers Squibb, CV 131-061: A Multi-Center Randomized Study of Irbesartan Compared with Lisinopril in Subjects with Heart Failure. (1997 - 1999)


15. Sub-Investigator , WYETH-AYERST Research Division Conducted through Kendle International Inc., Protocol 0927B2-916, Evaluation of Duration of Treatment on Echocardiograms in Patients Treated with Anorexigens for at least three Continuous Months. (1998 -1999)


16. Principal Investigator, IMPRESS, Protocol CV137-028 Inhibition of Metalloprotease (BMS-186716) in a Randomized Exercise and Symptoms Study in Subjects with Heart Failure (1998 - 1999)


17. Principal Investigator, Treating to New Targets (TNT), Parke-Davis (1998- )


18. Principal Investigator, CV123-211 A Double-Blind Comparison of 10,20,40 and 80 mg Doses of a Modified –Release Formulation of Pravastatin, of Atorvastatin 10 mg, and of Simvastatin 20 mg with Placebo in Hypercholesterolemic Patients, Bristol-Myers Squibb (1999-     )


19. Sub-Investigator, VALUE DioVan Antihypertensive Longterm Use Evaluation), Novartis (1999 -   )


20. Principal Investigator, CGP 48933 Multicenter, randomized, double blind, placebo-controlled, parallel trial to assess the effect of valsartan on exercise capacity, quality of life, and signs and symptoms, in patients with stable, chronic congestive heart failure (NYHA Class II-IV). Ciba-Geigy (1999 -2000)


21. Principal Investigator, OVERTURE Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events, Bristol-Myers Squibb (1999 -2001)


22. Sub-Investigator, VALIANT STUDY, Novartis – A multinational, multi-center, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high-risk patients after myocardial infarction(1999 - 2002)


23. Sub-Investigator, BMS CV137-066, A Randomized, Double-Blind, Amlodipine and Losartan controlled Study of Omapatrilat in Subjects with Mild to Moderate Hypertension (1999-2000)


24. Principal Investigator, ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens), Boehringer Ingelheim 1999- )


25. Principal Investigator, CV123-231, A Double-Blind Comparison of 80 and 160 mg Doses of Pravastatin with Placebo in Hypercholesterolemic Subjects Bristol-Myers Squibb (2000-    )


26. Sub-Investigator, ATA-201, A Multi-Center, Double-Blind Placebo Controlled Study of AT-1015 in Patients with Intermittent Claudication due to Peripheral Arterial Disease, Ajinomoto (2000-    )


27. Sub-Investigator, CV 154-008, Multicenter, Randomized, Double Blind Placebo-Controlled Dose Ranging Study of the Long Term (12 Weeks) Hemodynamic Effects, Safety and Tolerability of BMS-207940, A Selective Endothelin Receptor Antagonist, in the Treatment of Heart Failure Bristol-Myers Squibb (2000)


28. Principal Investigator, 981-400-421, SAGE, A Prospective, Randomized,Double-Blind, Multi-Center Study Comparing the Effects of Aggressive Lipid-Lowering with Moderate Lipid-Lowering on the Reduction of the Total Duration of Myocardial Ischemia in the Elderly as Measured by Holter Monitoring by Comparing the Maximal Doses of Two Statins: Study Assessing Goals in the Elderly, Parke-Davis/Pfizer (2000-    )


29. Principal Investigator, SCH58235, A Phase III Double-Blind Efficacy and Safety Study of SCH 58235 (10 mg) in addition to Atorvastatin in Subjects with Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin Schering-Plough (2000)


30. Principal Investigator, CV154-009, A Double-Blind Randomized Placebo-Controlled Study of the Efficacy and Safety of BMS-207940, A Selective Endothelin Receptor Antagonist, In Subjects with Intermittent Claudication, Bristol-Myers Squibb (2000- 2001)


31. Principal Investigator, GP00693, Phase II Double-Blind Efficacy and Safety Study of Ezetimibe (10 mg) + Atorvastatin in Subjects with CHD or Multiple Risk Factors and with Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin, Schering Plough Research Institute(2000)


32. Sub Investigator, ASSENT 3, Assessment of the Safety and Efficacy of New Thrombolytic Regimens, Boehringer-Ingelheim (2000-2001)


33. Sub-Investigator, 4522IL/0065, STELLAR, A 6-Week, Open-Label, Dose-Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin vs. Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects with Hypercholesterolemia (2001)


34. Sub-Investigator, 4522IL/0068, MERCURY II, An Open-Label, Randomized, Multi-Center, Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with Type IIa and IIb Hypercholesterolemia (2001)


35. Sub-Investigator, SYNERGY, A Prospective, Randomized, Open-Label, Multicenter Study In Patients Presenting with Acute Coronary Syndromes (ACS) (2002)


36. Sub-Investigator, Medtronics, (WAVE) Worldwide study of Marquis VR Enhancements (2003)


37. Sub-Investigator, Astra-Zeneca, (POLARIS) Open label randomized mulitcenter, Phase IIb, Parallel Group switching study to compare the efficacy and safety of lipid lowering agents Atorvastatin and Simvastatin with Rosuvastatin in high risk subjects with Type IIa and IIb Hypercholesterolemia. (2003-     )


38. Principal Investigator, Atherogenics, Inc., (ARISE), A prospective randomized, double-blind multi-center study comparing the effects of AGI 1067 versus placebo on the reduction of cardiovascular events in patients with Coronary Artery Disease (2003


39. Sub-Investigator, Medtronic A-HIRATE: Atrial High Rate Episodes in Pacemaker Patients


40. AMERIN PHARMA, INC:  AMR-01-01-0019  A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Disease or at High Risk for Cardiovascular Disease.  REDUCE IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)


41. Principal Investigator, Heart Rate Variability with Use of Psychostimulants in Attention Deficit Disorder. Children’s Hospital – LSU School of Medicine, New Orleans, Louisiana; West Jefferson Medical Center, Marrero, Louisiana. (2013- )